Search research articles
Contact Us
Filters
Showing results (191-200 of 587) with videos related to
Page
of 59
Sort By:
Neurotoxicology
|
December 31, 2003
Monoamine oxidase inhibition and CNS immunodeficiency infection
E Koutsilieri, C Scheller, V ter Meulen, et al.
Arzneimittel-Forschung
|
February 1, 1992
Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia
P Riederer, K W Lange, J Kornhuber, et al.
Neuropharmacology
|
December 1, 1981
Dopamine receptors and schizophrenia: the neuroleptic drug problem
G P Reynolds, P Riederer, K Jellinger, et al.
Brain Research
|
August 5, 1998
Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease
G Münch, A M Cunningham, P Riederer, et al.
European Journal of Pharmacology
|
December 12, 1991
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
M Gerlach, P Riederer, H Przuntek, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1991
Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis
P Riederer, K W Lange, J Kornhuber, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1978
Brain monoamines in hepatic encephalopathy and other types of metabolic coma
K Jellinger, P Riederer, W D Rausch, et al.
Infection
|
November 1, 1996
High prevalence of opportunistic infections in the head and neck related to human immunodeficiency virus. A prospective study of the distribution of otorhinolaryngologic disorders in 250 patients
A P Riederer, G O Grein, J R Bogner
Journal of Neural Transmission. Supplementum
|
January 1, 1995
Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders?
D Blum-Degen, L Frölich, S Hoyer, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1996
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline
M Gerlach, H Desser, M B Youdim, et al.
Page
of 59
Search research articles
Search
Showing results (191-200 of 587) with videos related to
Sort By:
Page
of 59
Neurotoxicology
|
December 31, 2003
Monoamine oxidase inhibition and CNS immunodeficiency infection
E Koutsilieri, C Scheller, V ter Meulen, et al.
Arzneimittel-Forschung
|
February 1, 1992
Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia
P Riederer, K W Lange, J Kornhuber, et al.
Neuropharmacology
|
December 1, 1981
Dopamine receptors and schizophrenia: the neuroleptic drug problem
G P Reynolds, P Riederer, K Jellinger, et al.
Brain Research
|
August 5, 1998
Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's disease
G Münch, A M Cunningham, P Riederer, et al.
European Journal of Pharmacology
|
December 12, 1991
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
M Gerlach, P Riederer, H Przuntek, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1991
Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosis
P Riederer, K W Lange, J Kornhuber, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1978
Brain monoamines in hepatic encephalopathy and other types of metabolic coma
K Jellinger, P Riederer, W D Rausch, et al.
Infection
|
November 1, 1996
High prevalence of opportunistic infections in the head and neck related to human immunodeficiency virus. A prospective study of the distribution of otorhinolaryngologic disorders in 250 patients
A P Riederer, G O Grein, J R Bogner
Journal of Neural Transmission. Supplementum
|
January 1, 1995
Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders?
D Blum-Degen, L Frölich, S Hoyer, et al.
Journal of Neural Transmission. Supplementum
|
January 1, 1996
New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline
M Gerlach, H Desser, M B Youdim, et al.
Page
of 59